The Company will host a conference call to discuss the results at 8:30 a.m. ET on February 5, 2025. CONSHOHOCKEN, Pa., January 02, 2025--Cencora, Inc. (NYSE: COR) today announced the completion of ...
Key Indicators: Cencora's Financial Health Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong ...
Mizuho started coverage on shares of Cencora in a research note on Wednesday, December 4th. They set an “outperform” rating and a $280.00 target price for the company. Robert W. Baird boosted ...
Walgreens Boots Alliance has sold more shares of drug distributor Cencora for proceeds of about $300 million, “primarily for debt paydown and general corporate purposes,” the company said ...
The latest sale netted about $300 million for Walgreens, and shrinks the company’s stake in Cencora to approximately 6%, down from 10%, according to a press release on Thursday. Walgreens said ...
Leerink Partnrs dropped their Q2 2025 EPS estimates for Cencora in a report released on Wednesday, February 5th. Leerink Partnrs analyst M. Cherny now forecasts that the company will earn $4.08 per ...
Feb 5 (Reuters) - Drug distributor Cencora (COR.N), opens new tab raised ... The Conshohocken, Pennsylvania-based company now expects its 2025 adjusted profit to range between $15.25 and $15. ...
For the next fiscal year, the company is expected to earn $16.52 per share on $339.6 billion in revenues. This represents a year-over-year change of 9.52% and 6.76%, respectively. Cencora may be ...
(AP) — Cencora, Inc. (COR) on Wednesday reported fiscal first-quarter net income of $488.6 million. The Conshohocken, Pennsylvania-based company said it had profit of $2.50 per share. Earnings ...
Get to know 2025 Diversity in Business honoree Ky’a Jackson, senior director of diversity, equity and inclusion at Cencora.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results